One Drug, a $350M Bet, Plus Cerebras' $26B Backlog | Tech Arcade Podcast
Dren Bio has raised $350 million for one antibody, dibotatug, built to remove only the rogue killer cells behind two rare blood cancers. We explain how it works, how far along it is, and the catch. Then Cerebras raises its 2026 forecast as cloud revenue more than triples and its backlog reaches $26.1 billion.
Full story: https://www.techarcade.io/dren-bio-raised-350-million-for-one-antibody-that-deletes-rogue-immune-cells/
Full story: https://www.techarcade.io/cerebras-just-raised-its-2026-forecast-to-960-million-and-the-stock-jumped-nearly-18-after/
Sources
https://drenbio.com/news.html
https://www.pharmaceutical-technology.com/newsletters/dren-bio-350m-dibotatug-clinical-development/
https://pharmaphorum.com/news/dren-bio-pockets-350m-rare-blood-cancer-programme
https://parsers.vc/news/261103-dren-bio-secures-350-million-for-advanced/
https://www.fiercebiotech.com/biotech/pfizer-joins-dren-bio-investors-65m-series-after-1b-oncology-collab-biotech
https://investors.cerebras.ai/news-releases/news-release-details/cerebras-systems-delivers-record-revenue-third-quarter-2026
https://www.marketscreener.com/news/cerebras-lifts-annual-sales-forecast-on-strong-ai-linked-demand-shares-surge-ce785ed9d98df025
Where sources differ: Dren Bio's release is datelined San Carlos, California, and says the money will fund a regulatory submission; it does not say the drug is nearing submission.
More at https://www.techarcade.io
#techarcade #biotech #DrenBio #Cerebras #AIchips


